“A soup of different inspirations”: co-produced research and recognising impact as a process, not an outcome.

Co-produced research involves external partners from start to finish, builds lasting relationships and is actively involved in generating impact. Yet co-production sits uncomfortably with how impact is currently understood. Rachel Pain and Ruth Raynor explore how the process of co-production has the potential to make research and its outcomes richer as collaborators pool diverse ideas, expertise and skills. Impact becomes the driving (and uniting) force behind research, rather than a separate after-product

The next REF should place greater value on the ‘impact-in-process’ generated by co-produced research.

Impact has in the past two REF cycles established itself as an integral criteria of research assessment in the UK. However, the kinds of impacts that are valued and the ways in which the ‘reach’ and ‘significance’ of impact are interpreted by institutions can conversely de-value certain kinds of transformative research. Taking this into account, Sonja Marzi and Rachel Pain argue for the importance of impact-in-process and the role research itself can play in producing meaningful changes in people’s lives

Mapping Alternative Impact: Alternative approaches to impact from co-produced research

No abstract available

Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases

Mesenchymal stem cells (MSCs) modulate immune responses and maintain self-tolerance. Their trophic activities and regenerative properties make them potential immunosuppressants for treating autoimmune and autoinflammatory diseases. MSCs are drawn to sites of injury and inflammation where they can both reduce inflammation and contribute to tissue regeneration. An increased understanding of the role of MSCs in the development and progression of autoimmune disorders has revealed that MSCs are passive targets in the inflammatory process, becoming impaired by it and exhibiting loss of immunomodulatory activity. MSCs have been considered as potential novel cell therapies for severe autoimmune and autoinflammatory diseases, which at present have only disease modifying rather than curative treatment options. MSCs are emerging as potential therapies for severe autoimmune and autoinflammatory diseases. Clinical application of MSCs in rare cases of severe disease in which other existing treatment modalities have failed, have demonstrated potential use in treating multiple diseases, including rheumatoid arthritis, systemic lupus erythematosus, myocardial infarction, liver cirrhosis, spinal cord injury, multiple sclerosis, and COVID-19 pneumonia. This review explores the biological mechanisms behind the role of MSCs in autoimmune and autoinflammatory diseases. It also covers their immunomodulatory capabilities, potential therapeutic applications, and the challenges and risks associated with MSC therapy.</jats:p